Clinical Evaluation of VeriSee AMD in Screening for Age-Related Macular Degeneration

Macular Degeneration, Age Related Clinical Trial

Official title:

A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee AMD) for Screening of Age-Related Macular Degeneration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05593913
• Other study ID #: AHCI21001
• Status: Completed
• Start date: January 17, 2022
• Est. completion date: August 10, 2022

Study information

• Verified date: April 2023
• Source: Acer Medical Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

An observational study is designed to evaluate the clinical performance of VeriSee AMD for potential age-related macular degeneration (AMD) screening from color fundus photography images. The sensitivity and specificity of VeriSee AMD's automated image analysis for screening AMD will be determined through the comparison with the gold standard, which is the judgment of AMD by the ophthalmologists.

Description:

This is a retrospective, single-center, observational study to assess the clinical performance of VeriSee AMD in screening for potential age-related macular degeneration (AMD).

Potential subjects with images of color fundus photography will be selected for eligibility, and then the ophthalmologist further confirms the images with legible quality. Three independent ophthalmologists (or evaluators) having more than 6 years of experience in retina will evaluate AMD from the color fundus photography images with different sequences of images independently. These three evaluators are different from the ophthalmologist who is responsible for deciding subject's eligibility. The evaluators determine the severity of AMD based on the four-level scale which is the AMD Severity Scale stated in Age-Related Eye Disease Study (AREDS) Report No. 6. Before the study, the training section is necessary to ensure the consensus of the AMD severity grading among three evaluators. The severity determined by the majority of the grade the three evaluators gave is considered the gold/reference standard in this study. Therefore, level 1 and level 2 are classified as non-mtl3AMD, while level 3 and advanced AMD (level 4) are classified as mtl3AMD. The clinical performance displayed as sensitivity and specificity will be determined by comparing the AMD results between VeriSee AMD and the gold standard.

VeriSee AMD is intended to screen AMD from the images taken by color fundus photography, which can assist the physicians to assess whether further examination for retinopathy by the ophthalmologist is needed. The screening result of AMD will be non-mtl3AMD or mtl3AMD for the physicians' reference and does not intend to diagnose AMD, detect concomitant diseases, or treat AMD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 986
• Est. completion date: August 10, 2022
• Est. primary completion date: March 3, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Subject with age = 50 years old

• Subject with image taken by color fundus photography that meet the following requirement:

1. The resolution of image is 271x271 pixels or higher;

2. The angle view of image is 45 or 50 degree.

• Subject's image includes macula as judged by the ophthalmologist.

Exclusion Criteria:

• The color fundus photography image previously used by VeriSee AMD during the development process and pre-clinical test

• The macula or other part in the image of color fundus photography is unclear to determine the disease condition as judged by the ophthalmologist.

Related Conditions & MeSH terms

• Macular Degeneration
• Maculopathy, Age Related

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
Acer Medical Inc.	National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity	To evaluate the clinical performance of VeriSee AMD by determining the sensitivity.; Sensitivity = 100% x TP/(TP+FN)	1 day
Primary	Specificity	To evaluate the clinical performance of VeriSee AMD by determining the Specificity.; Specificity = 100% x TN/(TN+FP)	1 day
Secondary	Positive Predictive Values (PPV)	To evaluate the clinical performance of VeriSee AMD by determining the positive predictive values (PPV).; Positive predictive value (PPV) =100% x TP/(TP+FP)	1 day
Secondary	Negative Predictive Values (NPV)	To evaluate the clinical performance of VeriSee AMD by determining the negative predictive values (NPV).; Negative predictive value (NPV) = 100% x TN/(FN+TN)	1 day
Secondary	The Percentage of Subjects' Images With Insufficient Quality as Judged by VeriSee AMD	The percentage of the images with insufficient quality as determined by VeriSee AMD will be presented.	1 day